

TOT/40

५२६

04-11-01

AlBok
Seg

1040 U.S. PRO
09/832320

04/10/01

UTILITY PATENT APPLICATION TRANSMITTAL (Only for new nonprovisional applications under 37 CFR 1.53(b))	Attorney Docket No. 35718/214291 (5718-183) First Inventor or Application Identifier: Edmund H. Crane, III Title of Invention: MAIZE PATHOGENESIS-RELATED POLYNUCLEOTIDE AND METHODS OF USE Express Mail Label No. EL613496094US
--	--

ADDRESS TO: **BOX PATENT APPLICATION
COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231**

Transmitted herewith for filing in the United States Patent Office is a patent application for:

Inventors: Emund H. Crane, III
405 Glenview Dr
Des Moines, IA 50312
Citizenship: USA

Virginia C. Crane
405 Glenview Dr
Des Moines, IA 50312
Citizenship: USA

Assignee of this invention is

1. The Filing Fee has been calculated as shown below:

 2. Applicant claims Small Entity Status. See 37 CFR 1.27.

No. Filed	No. Extra	Rate	Small Entity Fee 0	Large Entity Rate	Large Entity Fee 1
BASIC FEE			\$0		\$710
TOTAL CLAIMS:	13 - 20 =	0	X 9 = \$0	x 18 = \$0	
INDEP CLAIMS:	3 - 3 =	0	X 40 = \$0	x 80 = \$0	
[<input type="checkbox"/>] MULTIPLE DEPENDENT CLAIMS PRESENTED			+135 = \$		+270 = \$
*If the difference in Column 1 is less than zero, enter "0" in Column 2.			TOTAL \$		TOTAL \$ 710

- a. Fees required under 37 CFR 1.16 (National filing fees).
b. Fees required under 37 CFR 1.17 (National application processing fees).

- A check in the amount of \$ ___ for the filing fee is enclosed.

- The above filing fee will be paid along with Applicant(s) Response to the Notice to File Missing Parts.

3. Specification; Total Pages 92

4. Sheets of Formal Drawing(s) (35 USC 113)

5. Declaration and Power of Attorney; [*Total Pages* 1]
a. Newly executed (original or copy)
b. Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 18 completed)
i. DELETION OF INVENTOR(S) Signed statement attached deleting
inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) & 1.33(b).

6. Application Data Sheet. See 37 CFR 1.76

7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)

8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
a. Computer Readable Copy (CRF)
b. Request for Transfer of Computer Readable Form of Sequence Listing
under 37 CFR § 1.821(e) and MPEP 2422.05
c. Specification Sequence Listing on:
i. CD-ROM or CD-R (2 copies); or
ii. Paper (4 Pages)
d. Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. Assignment Papers (cover sheet & document(s) (including a check for the \$40.00 fee)

10. 37 CFR 3.73(b) Statement (*when there is an assignee*); Power of Attorney

11. English Translation Document (*if applicable*)

12. Information Disclosure Statement (IDS)/PTO-1449; ___ Copies of IDS Citations

13. Preliminary Amendment

14. Return Receipt Postcard (MPEP 503) (*Should be specifically itemized*)

15. Certified Copy of Priority Document(s) (*if foreign priority is claimed*)
Foreign Priority is

16. Request and Certification for Non-publication under 35 U.S.C. 122(b)(2)(B)(i).
Applicant **must** attach form PTO/SB35 or its equivalent.

17. Request for Early Publication Under 37 CFR § 1.219. Fee of \$300.00 is enclosed.

18. **If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:**
 Continuation Divisional Continuation in Part (CIP)

Prior Application Information: Examiner _____ Group/Art Unit: _____

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS . CUSTOMER NUMBER 000826

Signature: Kelly J. Williamson

Attorney/Agent of Record: Kelly J. Williamson

Attorney/Agent Registration No. 47,179

Alston & Bird LLP

Bank of America Plaza

101 South Tryon Street, Suite 4000

Charlotte, NC 28280-4000

Tel Raleigh Office (919) 420-2200

Fax Raleigh Office (919) 420-2260

"Express Mail" mailing label number EL613496094US

Date of Deposit April 10, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box Patent Application, Commissioner For Patents, Washington, DC 20231.

Pamela Lockley

Pamela Lockley

RTA01/2094316v1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Crane, et al.
Appl. No.: To Be Assigned
Filed: Concurrently Herewith
For: MAIZE PATHOGENESIS-RELATED POLYNUCLEOTIDE AND METHODS
OF USE

**STATEMENT IN SUPPORT OF FILING A
SEQUENCE LISTING UNDER 37 CFR § 1.821(f)**

Commissioner for Patents
Washington, DC 20231

Sir:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted concurrently herewith in accordance with 37 CFR § 1.821(c) and (e), are the same.

Respectfully submitted,




Kelly J. Williamson
Attorney/Agent for Applicant
Registration No. 47,179

Alston & Bird LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Raleigh Office (919) 420-2200
Fax Raleigh Office (919) 420-2260

"Express Mail" Mailing Label Number EL613496094US
Date of Deposit: April 10, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box Patent Application, Commissioner for Patents, Washington, DC 20231.



Pamela Lockley

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Washington, DC 20231, on April 10, 2001.